The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pericardial effusion (w/wo tamponade)
Publications
Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?
Clinical endocrinology 2011 May;74;608-10 — 2011 May — 608-10
Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
Heart (British Cardiac Society) 2004 Aug;90;e47 — 2004 Aug — e47
Fibrosis associated with dopamine agonist therapy in Parkinson's disease.
Clinical neuropharmacology 2003 May-Jun;26;109-11 — 2003 May-Jun — 109-11
Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
Mayo Clinic proceedings 1999 Apr;74;371-5 — 1999 Apr — 371-5